For the roughly 1 in 500 adults who carry an IgA nephropathy diagnosis, the trajectory toward dialysis or transplant has long felt inexorable despite supportive care. A large Phase 3 randomized trial now provides two-year evidence that blocking a specific arm of the immune complement system can meaningfully slow that decline — potentially redefining the standard of care for this leading cause of glomerular kidney failure worldwide.
The APPLAUSE-IgAN trial enrolled 477 adults with confirmed IgA nephropathy, preserved but impaired kidney function (eGFR ≥30 ml/min/1.73 m²), and persistent proteinuria despite optimized background therapy. Participants were randomized 1:1 to oral iptacopan 200 mg twice daily — a selective complement factor B inhibitor that interrupts the alternative pathway amplification loop — or matched placebo over 24 months. The annualized total eGFR slope, the primary endpoint for the final analysis, was −3.10 ml/min/1.73 m²/year in the iptacopan arm versus −6.12 ml/min/1.73 m²/year with placebo, representing roughly a 50% attenuation in the rate of kidney function loss. A composite kidney-failure endpoint including sustained ≥30% eGFR decline, dialysis initiation, transplant, or kidney-failure death also favored iptacopan in time-to-event analysis.
This result builds meaningfully on the 9-month interim data, which had already demonstrated a 38.3% reduction in proteinuria. What the full 24-month dataset adds is functional kidney preservation — an outcome that correlates directly with long-term survival and dialysis avoidance. IgA nephropathy pathophysiology involves complement-driven mesangial inflammation triggered by galactose-deficient IgA1 immune complexes, making factor B an attractive therapeutic node. Iptacopan's oral bioavailability distinguishes it from intravenous complement inhibitors already approved in other nephropathies. The trial population was already on maximized renin-angiotensin-aldosterone system blockade, making these additive gains clinically significant rather than methodologically artifact. Limitations include a 24-month horizon that, while longer than most nephrology trials, cannot yet confirm transplant-free survival benefits. This is a Phase 3 result published in the New England Journal of Medicine — the evidentiary tier that typically precedes regulatory action — and represents a potentially practice-changing advance.